Wedbush Maintains Outperform on Viridian Therapeutics, Raises Price Target to $42

Benzinga · 4d ago
Wedbush analyst Laura Chico maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $41 to $42.